| Previous close | 6.30 |
| Open | 6.30 |
| Bid | 4.80 |
| Ask | 7.90 |
| Strike | 92.50 |
| Expiry date | 2024-01-19 |
| Day's range | 6.30 - 6.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 142 |
- Zacks
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
- Zacks
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
- Motley Fool
Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock
Swiss drugmaker Novartis (NYSE: NVS) boasts a $207 billion market capitalization, which makes it the sixth-largest pharma stock in the world and the largest international-based pharma stock. Here are a few reasons income investors should consider adding this stock to their portfolios. Novartis had a decent second quarter for the period ended June 30.
© 2022 Yahoo. All rights reserved.
